DEFA14A 1 mnmd_letter__may_12_2023.htm DEFA14A DEFA14A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities

Exchange Act of 1934

Filed by the Registrant ☒

 

Filed by a Party other than the Registrant

 

Check the appropriate box:

 

Preliminary Proxy Statement

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

Definitive Proxy Statement

 

Definitive Additional Materials

 

Soliciting Material Pursuant to §240.14a-12

 

Mind Medicine (MindMed) Inc.

(Name of Registrant as Specified In Its Charter)

N/A

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check all boxes that apply):

 

No fee required

 

Fee paid previously with preliminary materials

 

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

On May 15, 2023, Mind Medicine (MindMed) Inc. (the “Company”) distributed a letter to shareholders in connection with the Company’s 2023 Annual General Meeting of Shareholders. A copy of the letter can be found below.:

img15439222_0.jpg 

 


 

img15439222_1.jpg 

 

 


 

img15439222_2.jpg 

 


 

img15439222_3.jpg 

 


 

img15439222_4.jpg 

__________________________________________________________________________________________________________